丹红注射液联合低分子肝素钙预防肺癌下肢深静脉血栓临床观察

Clinical observation on preventing deep vein thrombosis of lung with the Danhong injection plus the low molecular weight heparin

目的:探究丹红注射液联合低分子肝素钙预防肺癌下肢深静脉血栓的疗效。方法:选取我院于2012年3月-2014年1月收治的98例肺癌患者作为研究对象,将其按入院顺序平均分为A、B两组,A组实施丹红注射液联合低分子肝素钙进行治疗,B组采取一般基础治疗,分析两组患者下肢深静脉血栓的形成情况。结果:A组患者发生下肢深静脉血栓者占2.04%(1/49),并发肺血栓栓塞者占2.04%(1/49),与B组的20.41%(10/49)、10.20%(5/49)相比,A组患者发生LEDVT的概率较B组明显减少,并发PTE的概率相差不大。结论:丹红注射液联合低分子肝素钙对预防肺癌下肢深静脉血栓的形成具有突出疗效,值得在临床上推广使用。

Objective: To explore the efficiency of the Danhong injection plus the Low molecular weight heparin on deep vein thrombosis of lung. Methods: From March 2012 to January 2014, 98 cases of lung in our hospital were divided into the group A and group B. The group A was given the Danhong injection plus the Low molecular weight heparin treatment; the group B was given the fundamental treatment. The situations of deep vein thrombosis in two groups were analyzed. Results: In the group A, the patients of deep vein thrombosis was 2.04%(1/49), and concurrency pulmonary thromboembolism was 2.04%(1/49). In the group B, the patients of deep vein thrombosis was 20.41%(10/49), and concurrency pulmonary thromboembolism was 10.20%(5/49). The probability of LEDVT in the group A was less than that in the group B. The probability difference of concurrency PTE was not significant. Conclusion: The Danhong injection plus the Low molecular weight heparin preventing deep vein thrombosis of lung showed obvious efficiency, was worthy of promotion.